TABLE 8.
Frequency of each adverse event (AE) for the 44 COVID‐19 patients in the experimental group and the control group
| Experimental group (N = 26) | Control group (N = 18) | ||||
|---|---|---|---|---|---|
| Condition of AEs | Total (%) | ≥Grade 3 | Total (%) | ≥Grade 3 | P |
| Blood routine | |||||
| Increased CRP | 1 (1.79) | 0 | 0 (0) | 0 | 1.000 |
| Leukopenia | 3 (5.35) | 0 | 0 (0) | 0 | .258 |
| Thrombocytopenia | 1 (1.79) | 0 | 0 (0) | 0 | 1.000 |
| Thrombocytosis | 0 (0) | 0 | 1 (1.69) | 0 | .409 |
| Liver function | |||||
| Abnormal liver function | 4 (7.14) | 1 | 3 (5.09) | 1 | 1.000 |
| Elevated bilirubin | 0 (0) | 0 | 1 (1.69) | 0 | .409 |
| Hypoproteinemia | 2 (3.57) | 0 | 1 (1.69) | 0 | 1.000 |
| Increased alkaline phosphatase | 0 (0) | 0 | 1 (1.69) | 0 | .409 |
| Blood lipids | |||||
| Elevated triglycerides | 3 (5.35) | 0 | 4 (6.79) | 0 | .419 |
| Elevated cholesterol | 4 (7.14) | 0 | 0 (0) | 0 | .133 |
| Hyperlipidemia | 2 (3.57) | 0 | 1 (1.69) | 0 | 1.000 |
| Renal function | |||||
| Increased creatinine | 1 (1.79) | 0 | 2 (3.39) | 1 | .409 |
| Elevated uric acid | 0 (0) | 0 | 1 (1.69) | 0 | .409 |
| Myocardial enzymes | |||||
| Increased creatine kinase | 1 (1.79) | 0 | 0 (0) | 0 | 1.000 |
| Elevated lactate dehydrogenase | 1 (1.79) | 0 | 0 (0) | 0 | 1.000 |
| Coagulation | |||||
| Abnormal blood clotting function | 2 (3.57) | 0 | 5 (8.48) | 1 | 1.000 |
| Prothrombin time prolonged | 0 (0) | 0 | 1 (1.69) | 0 | .409 |
| Increased fibrinogen | 1 (1.79) | 0 | 0 (0) | 0 | 1.000 |
| Elevated blood sugar | 2 (3.57) | 0 | 0 (0) | 0 | .505 |
| Electrolyte disturbance | |||||
| Hypocalcemia | 1 (1.79) | 0 | 0 (0) | 0 | 1.000 |
| Hypokalemia | 2 (3.57) | 0 | 2 (3.39) | 0 | 1.000 |
| Low chlorine | 0 (0) | 0 | 2 (3.39) | 0 | .162 |
| Low sodium | 0 (0) | 0 | 2 (3.39) | 0 | .162 |
| Elevated blood sodium | 0 (0) | 0 | 1 (1.69) | 0 | .409 |
| Hyperkalemia | 2 (3.57) | 0 | 1 (1.69) | 0 | 1.000 |
| Clinical symptoms | |||||
| Fever | 1 (1.79) | 0 | 3 (5.09) | 0 | .289 |
| Diarrhea | 1 (1.79) | 0 | 1 (1.69) | 0 | 1.000 |
| Expiratory dyspnea | 2 (3.57) | 1 | 0 (0) | 0 | 1.000 |
| Respiratory failure | 1 (1.79) | 1 | 0 (0) | 0 | .505 |
| Cough | 3 (5.35) | 0 | 0 (0) | 0 | .258 |
| Anemia | 5 (8.92) | 0 | 7 (11.88) | 0 | .273 |
| Heart failure | 0 (0) | 0 | 1 (1.69) | 1 | .409 |
| Chest tightness | 1 (1.79) | 0 | 1 (1.69) | 0 | 1.000 |
| High blood pressure | 2 (3.57) | 0 | 6 (10.18) | 0 | .048* |
| ARDS | 1 (1.79) | 1 | 2 (3.39) | 2 | .558 |
| Shock | 3 (5.35) | 3 | 3 (5.09) | 3 | .676 |
| Gastrointestinal bleeding | 1 (1.79) | 1 | 1 (1.69) | 1 | 1.000 |
| Multifunctional organ failure | 2 (3.57) | 2 | 5 (8.48) | 5 | .103 |
| Total times | 56 (100) | 10 | 59 (100) | 15 | |
Note. Fisher's exact test to obtain the P value. ARDS, acute respiratory distress syndrome.
*
Represents significant difference (P < .05).